Cytek Non Current Liabilities Total from 2010 to 2024

CTKB Stock  USD 5.61  0.01  0.18%   
Cytek Biosciences' Non Current Liabilities Total is decreasing over the years with stable fluctuation. Overall, Non Current Liabilities Total is expected to go to about 67 M this year. From 2010 to 2024 Cytek Biosciences Non Current Liabilities Total quarterly data regression line had arithmetic mean of  86,977,955 and r-squared of  0.05. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
2010-12-31
Previous Quarter
48.4 M
Current Value
67 M
Quarterly Volatility
40.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 5.5 M, Interest Income of 8 M or Depreciation And Amortization of 9.7 M, as well as many indicators such as Price To Sales Ratio of 6.07, Dividend Yield of 0.0 or PTB Ratio of 3.3. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.
  
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

Latest Cytek Biosciences' Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of Cytek Biosciences over the last few years. It is Cytek Biosciences' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytek Biosciences' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Pretty Stable
   Non Current Liabilities Total   
       Timeline  

Cytek Non Current Liabilities Total Regression Statistics

Arithmetic Mean86,977,955
Geometric Mean79,051,376
Coefficient Of Variation46.30
Mean Deviation21,725,800
Median91,023,000
Standard Deviation40,270,371
Sample Variance1621.7T
Range184.7M
R-Value(0.22)
Mean Square Error1658.8T
R-Squared0.05
Significance0.42
Slope(2,016,999)
Total Sum of Squares22703.8T

Cytek Non Current Liabilities Total History

202467 M
202348.4 M
202244.9 M
202124.7 M
2020209.5 M

About Cytek Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cytek Biosciences income statement, its balance sheet, and the statement of cash flows. Cytek Biosciences investors use historical funamental indicators, such as Cytek Biosciences's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may use each financial statement separately, they are all related. The changes in Cytek Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytek Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cytek Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Total48.4 M67 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Cytek Stock

When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.658
Earnings Share
(0.09)
Revenue Per Share
1.497
Quarterly Revenue Growth
0.21
Return On Assets
(0.03)
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.